Welcome to our dedicated page for BIOHARVEST SCIENCES SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BIOHARVEST SCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BIOHARVEST SCIENCES's regulatory disclosures and financial reporting.
BioHarvest Sciences Inc. launched a preliminary prospectus supplement for a primary underwritten offering of common shares on Nasdaq under “BHST,” with Craig‑Hallum as sole managing underwriter and a 30‑day option for the underwriter to buy additional shares after effectiveness. The company, a foreign private issuer and emerging growth company, plans to use proceeds for research and development, manufacturing, marketing, advancing its CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes.
Management also shared preliminary Q3 2025 results and Q4 guidance. Q3 revenue is expected at approximately $9.1M, with adjusted EBITDA in a range of ($0.7M) to ($0.4M). For Q4 2025, revenue guidance is $9.0M to $9.5M, with adjusted EBITDA between ($0.6M) and $0.0M. Recently, the company signed a CDMO agreement with Saffron Tech to develop saffron‑derived compounds; Saffron Tech will own 75% of developed compositions and related IP, while BioHarvest will hold 25% and intends to manufacture and market resulting products.
BioHarvest Sciences Inc. (BHST) filed a Prospectus Supplement enabling the resale of up to 461,538 common shares by a selling shareholder. The company is not selling any securities and will not receive proceeds from these sales; the selling holder will receive all net proceeds, while the company covers registration expenses.
The registered shares were issued upon conversion of the holder’s Convertible Notes on September 19, 2025 at USD 6.50 per share. The selling shareholder may dispose of shares on Nasdaq or via private transactions at market, fixed, related, varying, or negotiated prices through ordinary brokerage transactions as described under Plan of Distribution.
BioHarvest’s common shares trade on Nasdaq under “BHST.” The last reported sale price was USD 12.03 on October 14, 2025. Company common shares to be outstanding after this offering are stated as 19,593,267.
BioHarvest Sciences Inc. filed a Form D reporting a Regulation D, Rule 506(b) exempt equity offering with total proceeds of $401,348, all of which have been sold and $0 remaining. The notice shows the first sale occurred on 2025-09-19 and reports 2 total investors, with a stated $0 in sales commissions and finders' fees. The issuer is a corporation organized in British Columbia, Canada and identifies multiple executive officers and directors at its Vancouver address. The offering was not conducted as part of a business combination, the issuer does not intend the offering to last more than one year, and no proceeds are disclosed as paid to officers, directors, or promoters.
BioHarvest Sciences Inc. (BHST) discloses an extensive set of business and financial risks in this prospectus supplement, emphasizing the company's negative operating cash flow and concerns about its ability to continue as a going concern. The filing lists the need for additional capital, reliance on key inputs and e-commerce channels (VINIA.com, VINIA.co.il and Amazon Marketplace), potential subscription volatility, regulatory and manufacturing compliance risks, clinical trial enrollment risks for nutraceutical/cosmeceutical products, intellectual property and patent expiration risks, possible dilution from future financings, and uncertainty about a liquid trading market for the common shares.